Jean-Marc Huët
Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31The business, the people and the ownership behind Lonza.
Business overview
Lonza provides services and technologies through its Integrated Biologics, Advanced Synthesis and Specialized Modalities businesses. These are its reported continuing operating segments.
Listed security
Board & management
Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Independent
Board of Directors as of 31 December 2025 As reported at 2025-12-31Chief Executive Officer
Executive Committee as of 31 December 2025 As reported at 2025-12-31Roles listed in Annual Report 2025; current appointments are not independently verified.
Holdings
New York, NY (USA); held 9.85% of Lonza's share capital
Principal Shareholders; more than 3% of share capital per disclosure notificationsBasel, Switzerland; held 6.246% of Lonza's share capital
Principal Shareholders; more than 3% of share capital per disclosure notificationsTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Group structure
| Company | Market | Ownership interest |
|---|---|---|
| BioAtrium AGHolding Indirect | Visp CH; holding indirect 50% | |
| Capsugel Australia Pty LtdHolding Indirect | Sydney AUS; holding indirect 100% | |
| Capsugel Belgium NVHolding Indirect | Bornem BE; holding indirect 100% | |
| Capsugel Canada Corp.Holding Indirect | Vancouver CA; holding indirect 100% | |
| Capsugel Italy SrlHolding Indirect | Milan IT; holding indirect 100% | |
| Capsugel de México, S. de R.L. de C.V.Holding Indirect | Puebla ME; holding indirect 100% | |
| Capsugel Distribucion, S. de R.L. de C.V.Holding Indirect | Puebla ME; holding indirect 100% | |
| Capsugel France SASHolding Indirect | Colmar FR; holding indirect 100% | |
| Capsugel Healthcare Private LimitedHolding Indirect | Gurugram IN; holding indirect 99.9% | |
| Komec N.V.Holding Indirect | Wilrijk BE; holding indirect 100% | |
| LLC CapsugelHolding Indirect | Kuzminki (city of Moscow) RU; holding indirect 100% | |
| Lonza AGHolding Indirect | Visp CH; holding indirect 100% | |
| Lonza Bend lnc.Holding Indirect | Portland US; holding indirect 100% | |
| Lonza Biologics IncHolding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Biologics Ltd.Holding Indirect | Guangzhou CN; holding indirect 100% | |
| Lonza Biologics plcHolding Indirect | Slough GB; holding indirect 100% | |
| Lonza Biologics Porriño S.L.Holding Indirect | Porriño ES; holding indirect 100% | |
| Lonza Biologics Tuas Pte. Ltd.Holding Indirect | Singapore SG; holding indirect 100% | |
| Lonza Bioscience Singapore Pte LtdHolding Indirect | Singapore SG; holding indirect 100% | |
| Lonza Cologne GmbHHolding Indirect | Cologne DE; holding indirect 100% | |
| Lonza Costa Rica, S.A.Holding Indirect | Heredia CR; holding indirect 100% | |
| Lonza Finance International NVHolding Indirect | Bornem BE; holding indirect 100% | |
| Lonza Greenwood LLCHolding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Guangzhou Pharmaceutical LtdHolding Indirect | Guangzhou CN; holding indirect 100% | |
| Lonza Houston Inc.Holding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Licences AGHolding Indirect | Basel CH; holding indirect 100% | |
| Lonza K.K.Holding Indirect | Sagamihara JP; holding indirect 100% | |
| Lonza Manufacturing LLCHolding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Netherlands B.V.Holding Indirect | Geleen NL; holding indirect 100% | |
| Lonza Rockland, Inc.Holding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Sales AGHolding Direct | Basel CH; holding direct 100% | |
| Lonza Shanghai International Trading Ltd.Holding Indirect | Shanghai CN; holding indirect 100% | |
| Lonza Swiss Finanz AGHolding Indirect | Basel CH; holding indirect 100% | |
| Lonza Swiss Licences AGHolding Indirect | Basel CH; holding indirect 100% | |
| Lonza Tampa LLCHolding Indirect | Wilmington US; holding indirect 100% | |
| Lonza (Thailand) Co., Ltd.Holding Indirect | Bangkok TH; holding indirect 100% | |
| Lonza USA Inc.Holding Indirect | Wilmington US; holding indirect 100% | |
| Lonza Verviers SRLHolding Indirect | Verviers BE; holding indirect 100% | |
| Lonza Walkersville, Inc.Holding Indirect | Wilmington US; holding indirect 100% | |
| Micro-Macinazione SAHolding Indirect | Monteggio CH; holding indirect 100% | |
| Octane Biotech, Inc.Holding Indirect | Ontario CA; holding indirect 80% | |
| P.T. Capsugel IndonesiaHolding Indirect | Jakarta IN; holding indirect 100% | |
| Suzhou Capsugel LimitedHolding Indirect | Suzhou CN; holding indirect 75% | |
| Synaffix B.V.Holding Indirect | Oss NL; holding indirect 100% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Wolfgang Wienand | Chief Executive Officer | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Philippe Deecke | Chief Financial Officer | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Maria Soler Nunez | Chief Quality Officer | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Nicoleta Baumgärtner | Chief Human Resources Officer | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Andreas Bohrer | Chief Legal & Corporate Affairs Officer | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Jason Berndt | Head of Group Operations | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Gordon Bates | Head of Integrated Biologics | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Christian Seufert | Head of Advanced Synthesis | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Daniel Palmacci | Head of Specialized Modalities | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
| Jean-Christophe Hyvert | Head of Capsules & Health Ingredients | Executive Committee as of 31 December 2025 · As at 2025-12-31 | PDF p. 111 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Average number of employees (Full-Time Equivalent) | 16,866 FTE | Group, continuing business, 2025 (comparative 2024 restated: 15,734) | PDF p. 50 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Share buyback program | The Company intends to initiate a share buyback program for CHF 500 million spanning 12 months, following the receipt of the proceeds from Lone Star Funds. | Lonza Group Ltd | PDF p. 80 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| The Year Ahead | we are well positioned to continue executing our | CEO letter | PDF p. 5 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Corporate information